Journal of Cosmetic Dermatology最新文献

{"title":"Evaluation of Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Therapy in Patients With Mild Patch-Type Alopecia Areata","authors":"Ramazan Ülker,&nbsp;İlknur Yorğun Özdemir,&nbsp;Hatice Uce Özkol","doi":"10.1111/jocd.71120","DOIUrl":"https://doi.org/10.1111/jocd.71120","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Alopecia areata is a long-term autoimmune disease that causes hair loss in approximately 2% of people but does not result in permanent scarring. Intralesional corticosteroid treatment provides effective results; however, long-term use may lead to skin atrophy and telangiectasia. Platelet-rich plasma (PRP), an autologous blood-derived preparation, represents a patient-specific alternative that avoids steroid-related side effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To compare the efficacy and safety of intralesional PRP and intralesional triamcinolone acetonide (ILTA) in patients with mild patch-type (S1) alopecia areata.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study included patients aged 18–65 years with mild patch-type alopecia areata who were admitted to our clinic between March 2024 and March 2025 and had not received any previous treatment. Patients were allocated into two groups; both groups received a total of three sessions of treatment every 4 weeks. The primary endpoint was the change in SALT score from baseline to the 6th month. Secondary endpoints included the change in SALT score at the 3rd month, clinical response categories, hair pull test conversion, relapse rate during 6-month follow-up, and the adverse-event profile. SALT scores were calculated at baseline, 3 months, and 6 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty patients (41 males, 19 females; mean age 27.97 ± 7.36 years) completed the study. SALT scores decreased significantly in both groups (<i>p</i> &lt; 0.001). The score decreased from 6.03 to 0.93 in the PRP group and from 6.07 to 1.27 in the ILTA group, with no statistically significant difference between groups (mean difference 0.30; 95% CI −0.77 to 1.37; <i>p</i> = 0.576). The very good response rate (≥ 75% improvement) at six months was 76.67% in the PRP group and 66.67% in the ILTA group. Relapse occurred in 3 of 60 patients (5.0%) during the 6-month follow-up (1/30 (3.33%) in the PRP group and 2/30 (6.67%) in the ILTA group). Both groups experienced only mild adverse events; no serious side effects were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In mild untreated patch-type alopecia areata, PRP showed similar efficacy to intralesional triamcinolone acetonide and may be considered an alternative treatment option for mild patch-type alopecia areata.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recombinant Human Collagen in Clinical Medicine","authors":"Kyu-Ho Yi,&nbsp;Jong Keun Song,&nbsp;Hongseok Kim","doi":"10.1111/jocd.71092","DOIUrl":"https://doi.org/10.1111/jocd.71092","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Collagen is the dominant structural protein of vertebrate connective tissues and a central biomaterial in skin, cornea, tendon, cartilage, bone, vessel, oral mucosa, and wound repair. Traditional collagen products have largely been extracted from bovine, porcine, fish, or other animal tissues. Although animal-derived collagens have a long clinical history, they have limitations including batch variability, residual nonhuman epitopes, possible immunogenicity, pathogen-related concerns, ethical constraints, and limited molecular engineering. Recombinant human collagen has emerged as a synthetic-biology alternative designed to reproduce full-length human collagen chains, selected human collagen domains, or engineered humanized collagen-like sequences in controlled expression systems.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This systematic review and narrative synthesis summarizes the biological basis, production methods, molecular types, benefits, clinical applications, aesthetic uses, safety considerations, and translational limitations of recombinant human collagen, with emphasis on dermatology, wound healing, corneal regeneration, tissue engineering, injectable aesthetics, and dermal rejuvenation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A PRISMA-informed systematic search was performed across biomedical databases, publisher platforms, and regulatory sources for literature on recombinant human collagen, recombinant humanized collagen, recombinant type I collagen, recombinant type III collagen, recombinant collagen hydrogels, collagen-based medical devices, dermal fillers, wound healing, corneal substitutes, tissue engineering, photoaging repair, and aesthetic applications. Because the evidence base includes heterogeneous manufacturing papers, in vitro studies, animal experiments, early clinical trials, case series, and regulatory documents, quantitative meta-analysis was not performed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Recombinant human collagen offers human-sequence design, reduced animal-origin risk, improved batch consistency, scalable manufacturing potential, and engineering flexibility. Type I and type III recombinant collagens are most relevant to dermal, wound, tendon, corneal, and aesthetic applications, whereas type IV, VII, and XVII collagens are increasingly relevant to basement membrane and epidermal adhesion biology. Production remains technically demanding because native collagen requires triple-helix formation and post-translational modifications such as proline hydroxy","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q-Switched 1064-nm Laser Versus Picosecond 1064-nm Laser in Tattoo Removal: Comparable Overall Effectiveness With Higher Excellent Clearance Rates and Fewer Treatment Sessions for the Picosecond Laser","authors":"Jiaoquan Chen,&nbsp;Yingxue Liu,&nbsp;Yeqing Gong,&nbsp;Shaoyin Ma,&nbsp;Bihua Liang,&nbsp;Huilan Zhu","doi":"10.1111/jocd.71098","DOIUrl":"https://doi.org/10.1111/jocd.71098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Laser tattoo removal is becoming more popular, with the Q-switched (QS) 1064-nm nanosecond laser considered the traditional standard. While the picosecond (PS) 1064-nm laser offers an alternative for optimizing treatment protocols, comparative data regarding its relative efficacy remain limited and inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aims to evaluate and compare the clinical efficacy and safety profiles of QS 1064-nm laser and PS 1064-nm laser for tattoo removal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted on 130 patients with tattoos between January 2015 and September 2024 in a hospital. Participants received either QS 1064-nm laser (<i>n</i> = 57) or PS 1064-nm laser (<i>n</i> = 73) therapy. Efficacy was measured utilizing a four-grade clearance scale (poor to excellent), and adverse effects were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The PS 1064-nm laser achieved significantly higher excellent clearance (78.1% vs. 54.4%, <i>p</i> = 0.029) and required fewer median sessions (3 vs. 4, <i>p</i> = 0.020). Although the overall effectiveness rate (&gt; 50% clearance) was higher for the PS 1064-nm laser (94.52%) than for the QS 1064-nm laser (85.96%), this trend did not reach statistical significance (<i>p</i> = 0.094). After adjusting for baseline color imbalance (<i>p</i> = 0.061), a subgroup analysis of blue/black tattoos (<i>n</i> = 108) showed PS 1064-nm laser had significantly greater excellent clearance (80% vs. 55.8%, <i>p</i> = 0.007), with comparable overall effectiveness (93.9% vs. 88.4%, <i>p</i> = 0.314). Both treatments maintained excellent safety performance; reported side effects were limited to transient erythema/edema, with no severe complications reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The PS 1064-nm laser showed comparable overall effectiveness to the QS 1064-nm laser, with advantages in excellent clearance and fewer sessions. Limitations include predominantly blue/black tattoos and a 3-month follow-up, necessitating prospective validation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148647700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is More Energy Reliably Better in Energy-Based Aesthetic Practice?","authors":"Kyu-Ho Yi","doi":"10.1111/jocd.71084","DOIUrl":"https://doi.org/10.1111/jocd.71084","url":null,"abstract":"&lt;p&gt;In energy-based aesthetic practice, patients may assume that a stronger energy setting will produce better tightening or faster collagen remodeling. This assumption is biologically incomplete. More energy is not reliably better; the clinically relevant goal is an anatomically appropriate thermal dose that is sufficient to induce tissue remodeling while remaining within device-specific and tissue-specific safety limits. The clinician's task is to match energy delivery, electrode configuration, treatment depth, pass number, and tissue response to the target indication while avoiding unnecessary injury to skin, fat, vessels, nerves, bone, and sensitive aesthetic subunits.&lt;/p&gt;&lt;p&gt;In this commentary, thermal dose refers to the cumulative biological effect of heat exposure, determined by temperature, exposure time, tissue depth, heat distribution, cooling, impedance, hydration, and local tissue characteristics. It is therefore different from the displayed device output or peak energy setting. This commentary primarily focuses on RF-based aesthetic procedures, including monopolar RF (radiofrequency), bipolar RF, and RF microneedling. HIFU/MFU and lasers are mentioned only as related thermal technologies because their mechanisms of energy delivery, depth targeting, tissue interaction, and safety profiles differ substantially. Energy settings across RF, HIFU/MFU, RF microneedling, and lasers should not be directly compared.&lt;/p&gt;&lt;p&gt;Displayed energy settings do not directly equal biological dose, because tissue response is influenced by impedance, hydration, electrode–tissue contact, cooling, tissue thickness, local perfusion, treatment duration, and anatomical location. Collagen remodeling occurs within a therapeutic window: Insufficient heating may fail to stimulate remodeling, whereas excessive exposure may cause pain, inflammation, fat injury, burns, scarring, prolonged edema, dysesthesia, or other complications. Therefore, stronger settings are not inherently superior and should be used only when the target tissue, treatment endpoint, device labeling, and patient-specific anatomy justify them.&lt;/p&gt;&lt;p&gt;Immediate swelling, heat, pain, erythema, or transient tightness should not be interpreted as proof of effective collagen remodeling because true extracellular matrix remodeling evolves over weeks to months.&lt;/p&gt;&lt;p&gt;The dose–response relationship is also tissue-specific and indication-specific. Dermal tightening, scar remodeling, sebaceous modulation, adipose heating, and lifting-oriented treatments require different depths, degrees of heating, and safety margins. A setting appropriate for thicker submental tissue may be excessive in the infraorbital cheek, temple, mandibular border, or other thin-tissue regions. RF-based treatment should therefore be practiced as anatomical dose prescription rather than parameter escalation.&lt;/p&gt;&lt;p&gt;Thermal dose depends on both temperature and exposure time. Connective-tissue and energy studies show that collagen contraction,","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target the Muscle, Not the Wrinkle: Botulinum Neurotoxin in Facial Anatomy","authors":"Kyu-Ho Yi,&nbsp;Kim Hongeok","doi":"10.1111/jocd.71090","DOIUrl":"https://doi.org/10.1111/jocd.71090","url":null,"abstract":"&lt;p&gt;The question of whether botulinum toxin should be injected at the lateral canthus or more laterally into the orbicularis oculi muscle (OOc) is not a minor point of technique. It is a conceptual question about what an aesthetic injector believes the target is.&lt;/p&gt;&lt;p&gt;The visible wrinkle is the endpoint of a dynamic process; it is not necessarily the site where that process should be interrupted. A lateral canthal line is made visible by repeated folding of thin periorbital skin over a contracting sphincteric muscle, by tension from the lateral canthal tendon and orbital rim, and by the way smiling or squinting recruits neighboring midface muscles. Therefore, the most clinically relevant target is not simply the crease. It is the active motor unit and the vector of contraction that produces the crease.&lt;/p&gt;&lt;p&gt;This distinction matters because the lateral canthus is an anatomically crowded region. The eyelid margin, palpebral orbicularis, orbital orbicularis, canthal tendon, orbital septum, lacrimal gland region, venous structures, and zygomatic smile elevators all sit within a small treatment field. An injection that is too close to the eye, too medial, too deep, or too inferior may still be inside the area called “crow's feet,” but it can be outside the ideal muscle target. Conversely, a point that seems slightly lateral to the visible crease may be a better target if it lies in the thicker, contracting lateral orbital orbicularis oculi. The practical message is simple: do not inject the wrinkle; interpret the wrinkle.&lt;/p&gt;&lt;p&gt;Regulatory labeling reflects this principle. The current United States prescribing information for BOTOX Cosmetic describes injections for lateral canthal lines into the lateral orbicularis oculi muscle, with the needle oriented away from the eye, using three sites per side, and with the first site approximately 1.5–2.0 cm temporal to the lateral canthus and just temporal to the orbital rim [&lt;span&gt;1&lt;/span&gt;]. These directions should not be copied uncritically across all products, countries, and patients, because botulinum toxin preparations are not interchangeable unit for unit. Nevertheless, the anatomy behind the instruction is clinically important: the landmark is the lateral canthus, but the target is the lateral orbicularis oculi.&lt;/p&gt;&lt;p&gt;The observation that the lateral orbicularis oculi can be thicker is supported by recent anatomical review and ultrasonographic work [&lt;span&gt;2, 3&lt;/span&gt;]. Piao et al. used ultrasonography in healthy Korean volunteers and measured the orbicularis oculi muscle at serial lateral canthal landmarks. Their reported mean muscle thickness increased from 0.7 ± 0.3 mm at point A to 1.1 ± 0.3 mm at point B and 1.2 ± 0.3 mm at point C; the corresponding depths from the skin surface were 2.0 ± 0.4 mm, 2.8 ± 0.4 mm, and 3.1 ± 0.5 mm, respectively [&lt;span&gt;3&lt;/span&gt;]. The most accurate clinical phrasing is that the more lateral measured portion at the lateral canthal level was thicker than the more medial mea","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148647932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 1064 nm Fractional Q-Switched Laser and Topical Isotretinoin: A Split-Face Randomized Clinical Trial","authors":"Gita Faghihi,&nbsp;Maryam Aghaei,&nbsp;Hamid Varastehpour,&nbsp;Sarah Seyedyousefi,&nbsp;Bahareh Abtahi-Naeini","doi":"10.1111/jocd.71017","DOIUrl":"https://doi.org/10.1111/jocd.71017","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Acne scars are a common complaint amongst dermatology patients and treating these scars effectively can still be challenging. Multiple treatment approaches can be used on this matter, one of which is using various types of lasers. On the other hand, one of the most effective medical treatments for acne is topical retinoids, which can improve acne and prevent scarring. This study aimed to compare the combined effect of 1064 nm fractional Q-Switched Laser and topical isotretinoin with 1064 nm fractional Q-Switched Laser alone in the treatment of acne scars.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>In this randomized clinical trial, 20 patients with bilateral acne scars were treated with Q-Switched laser on one side of the face and Q-Switched laser combined with topical isotretinoin on the other. Treatments were performed every 2 weeks for a total of three sessions. Scar improvement was assessed at 3 and 6 months by a blinded assessor concerning clinical features and using dermoscopic images by Fotofinder dermoscope. Statistical analyses were performed using repeated measures ANOVA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty patients (16 female and 4 male) with a mean age of 36.55 finished the study. The side treated with the combination therapy showed significantly better scar scores and percent change at both 3 and 6 months compared to the side treated with laser alone treatment (39.0 ± 2.60 vs. 23.9 ± 1.90; <i>p</i>-value &lt; 0.001 after 6 months of treatment). No severe adverse effects were observed. Only one patient experienced transient erythema.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The combination of topical isotretinoin and Fractional Q-Switched 1064 nm laser was more effective than the laser alone in reducing acne scars, with minimal side effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Need for Objective Quantitative Pigment Assessment in Comparative Laser Trials for Melasma","authors":"Tansha Anand,&nbsp;Neelshan Anand","doi":"10.1111/jocd.71112","DOIUrl":"https://doi.org/10.1111/jocd.71112","url":null,"abstract":"&lt;p&gt;We read with great interest the recent randomized double-blind split-face trial by Wu et al., which compared 1064-nm picosecond neodymium-doped yttrium aluminum garnet (Nd:YAG) laser and 1064-nm Q-switched Nd:YAG laser for the treatment of melasma in Asian women. The authors should be commended for conducting a well-designed prospective randomized study with blinded results assessment and a split-face methodology, both of which strengthen the internal validity of the comparison. Their findings suggest that both laser modalities greatly improved melasma severity without statistically meaningful differences in efficacy, while picosecond treatment was linked with lower procedural pain.&lt;/p&gt;&lt;p&gt;Nevertheless, we would like to highlight a significant methodological consideration that may influence the interpretation of these outcomes. The study primarily evaluated treatment efficacy using the hemi-modified Melasma Area and Severity Index (hemi-mMASI) and the Global Aesthetic Improvement Scale (GAIS). Although these are widely accepted clinical outcome measures and the investigators improved reliability by employing two blinded dermatologists, both assessments remain largely dependent on clinical observation and subjective interpretation. As a result, subtle changes in pigmentation may not be appropriately assessed, particularly when comparing two treatment modalities that show relatively similar clinical performance.&lt;/p&gt;&lt;p&gt;Melasma is a complex pigmentary disorder characterized by heterogeneous epidermal, dermal, and mixed pigmentation. Clinical severity scores are significant for routine assessment; however, they cannot directly quantify melanin content or objectively differentiate small changes in pigment distribution. Modern non-invasive imaging techniques, including reflectance spectrophotometry, colorimetric analysis, Mexameter measurements, standardized dermoscopy, and reflectance confocal microscopy, provide reliable quantitative information regarding pigment intensity and distribution that complements conventional clinical scoring systems. Such objective methods have increasingly been recommended in pigmentary disorder research because they decrease observer-dependent heterogeneity and enhance the sensitivity for detecting treatment-related changes, particularly in comparative clinical trials including laser therapies [&lt;span&gt;1, 2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;This acknowledgment is particularly relevant in the present study because the observed variations between picosecond and Q-switched Nd:YAG lasers were consistently numerical rather than statistically significant. In studies with relatively small sample sizes, minor improvements in pigmentation may remain undetected when result evaluation relies predominantly on subjective clinical scores. Incorporating objective pigment quantification alongside validated clinical indices could therefore enhance statistical precision and provide a more comprehensive assessment of treatment efficacy. Such multimodal evalua","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71112","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Photobiomodulation and Light Therapy in Enhancing Burn Wound Recovery","authors":"Edwin Chrabieh,&nbsp;Mahmoud El Hajj,&nbsp;Saif Emsieh,&nbsp;Hazem Omaish,&nbsp;Mazen Kurban","doi":"10.1111/jocd.71040","DOIUrl":"https://doi.org/10.1111/jocd.71040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Photobiomodulation (PBM) is a non-invasive treatment using low-intensity red or near-infrared light to stimulate tissue repair and reduce inflammation. While used in aesthetic and rehabilitative medicine, its role in burn wound healing remains underexplored. Given biological parallels between post-injury remodeling and cosmetic rejuvenation, a systematic review of PBM in burn care is warranted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To evaluate the clinical effectiveness, safety, and outcomes of PBM—such as low-level laser and light-emitting diode (LED) therapy—in human burn patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of Ovid MEDLINE, Embase, and LILACS was conducted up to 2024. The MEDLINE search was conducted via Ovid MEDLINE, which includes all records indexed in PubMed, ensuring comprehensive coverage of the biomedical literature. Studies were included if they investigated PBM in human burn patients and reported at least one clinical outcome. Two reviewers independently screened studies; a third resolved conflicts. Risk of bias was assessed using a modified Cochrane tool. Due to outcome heterogeneity, narrative synthesis was performed. A binary heatmap visualized patterns across six domains: wound area, healing time, pain (VAS), scar quality (VSS), patient satisfaction, and adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven studies involving 190 patients were included. Healing time and pain (VAS) were most frequently reported, followed by wound area and scar quality. Only one study assessed patient satisfaction, and adverse events were inconsistently reported. PBM showed promising effects, including reduced healing time and pain. However, limited comparable data precluded meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PBM appears to be a promising adjunct in burn care, with benefits in healing, pain, and scar remodeling. However, methodological limitations, dosing variability, and inconsistent outcome reporting limit conclusions. High-quality, standardized trials using validated patient-reported outcomes are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Intensity Focused Ultrasound for Botulinum Toxin-Induced Ptosis: A Retrospective Pilot Case Series","authors":"Mojtaba Nasimi,&nbsp;Farideh Nasiri","doi":"10.1111/jocd.71109","DOIUrl":"https://doi.org/10.1111/jocd.71109","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Botulinum toxin-induced ptosis is a recognized complication of aesthetic injections that may adversely affect cosmetic outcomes and patient satisfaction. Pharmacologic management is limited and primarily aims to provide temporary elevation of the upper eyelid through stimulation of Müller's muscle. High-intensity focused ultrasound (HIFU) has established applications in facial tissue tightening and may represent a potential non-pharmacologic treatment option.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the clinical outcomes of botulinum toxin-induced ptosis treated with HIFU using the ULTRAcel Q+ system.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective pilot case series included five consecutive patients with botulinum toxin-induced ptosis treated using a standardized HIFU protocol with the ULTRAcel Q+ system (3-mm dot handpiece, energy level 0.7, 12 shots). Clinical outcomes were evaluated using standardized photographs obtained under controlled imaging conditions. Margin Reflex Distance 1 (MRD1), defined as the distance between the corneal light reflex and the upper eyelid margin in primary gaze. Eyebrow position was also evaluated by comparing brow height relative to the supraorbital rim and facial symmetry. Both were measured at baseline, immediately after treatment, and during follow-up through Day 21.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Five patients (4 females, 1 male; mean age 38.4 years) were included. All had received Dysport injections (130–150 units) to the glabella, forehead, and crow's feet regions. Ptosis onset occurred 3–7 days after injection. HIFU was performed 3–6 days after symptom onset. Mean MRD1 increased from 0.76 mm at baseline to 1.98 mm immediately after treatment, 2.30 mm at Day 7, 4.18 mm at Day 14, and 4.44 mm at Day 21. Three patients presented with isolated eyelid ptosis, whereas two had combined eyelid and eyebrow ptosis. All patients demonstrated complete clinical resolution by Day 14. Mild transient procedural pain occurred during treatment, and no long-term treatment-related adverse events were observed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this retrospective pilot case series, HIFU using the ULTRAcel Q+ system was associated with complete clinical resolution of botulinum toxin-induced ptosis by Day 14 and was well tolerated. Unlike pharmacologic agents such as oxymetazoline, which temporarily elevate the eyelid throu","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Oral Herbal Supplementation on Human Skin Aging: A Systematic Review of Clinical Trials","authors":"Gisela Meydilin Sanjaya,&nbsp;Brilian Veda Kartika Putri,&nbsp;Hany Anneke,&nbsp;Nayla Majeda Alfarafisa,&nbsp;Astrid Feinisa Khairani,&nbsp;Nur Atik","doi":"10.1111/jocd.71094","DOIUrl":"https://doi.org/10.1111/jocd.71094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Skin aging, characterized by wrinkles, decreased elasticity, and dryness, is both a public health and esthetic issue, affecting most adults and leading to lowered quality of life and higher healthcare costs. While topical treatments are common, systemic approaches are gaining interest for their potential to enhance skin hydration, elasticity, and barrier function. Nonetheless, the effects of oral herbal supplements remain less examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This systematic review evaluated the effectiveness of oral herbal supplements in reducing skin aging in humans, focusing on elasticity, hydration, wrinkle depth, and antioxidant activity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Randomized controlled trials (RCTs) were identified through structured database searches (March–August 2025). Twelve RCTs published between 2020 and 2025 met the inclusion criteria, involving adults who received oral herbal supplements versus placebo or standard care. Outcomes measured included skin elasticity, hydration, wrinkle depth, smoothness, antioxidant capacity, and inflammatory markers. Quality assessment using the Cochrane RoB 2 tool indicated that all 12 RCTs were judged as having <i>some concerns</i> of bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Interventions included <i>Glycine max</i>, bilberry, cranberry, Hydrangea serrata, Pycnogenol, and others. Most studies reported significant improvements in dermatological outcomes. Proposed mechanisms involve antioxidant activity, anti-inflammatory effects, collagen synthesis, barrier restoration, photoprotection, DNA repair, and microbiome modulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, oral herbal supplements show promising potential in improving skin aging outcomes by targeting multiple biological pathways. Further research with larger populations, longer durations, and biomarker-based endpoints is needed to confirm efficacy and support standardized use in dermatology and esthetic medicine.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 8","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}